Heart Test Financials

HSCSW Stock  USD 0.04  0.01  19.24%   
Based on the key indicators related to Heart Test's liquidity, profitability, solvency, and operating efficiency, Heart Test Laboratories may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter. At this time, Heart Test's Inventory is fairly stable compared to the past year. Other Current Assets is likely to climb to about 1.1 M in 2025, whereas Other Current Liabilities is likely to drop slightly above 627.4 K in 2025. Key indicators impacting Heart Test's financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Current Ratio3.973.78
Sufficiently Up
Slightly volatile
The financial analysis of Heart Test is a critical element in measuring its lifeblood. Investors should not minimize Heart Test's ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.

Net Income

(6.24 Million)

  
Understanding current and past Heart Test Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Heart Test's financial statements are interrelated, with each one affecting the others. For example, an increase in Heart Test's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Heart Test's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Heart Test Laboratories. Check Heart Test's Beneish M Score to see the likelihood of Heart Test's management manipulating its earnings.

Heart Test Stock Summary

Heart Test competes with Heart Test, Inspira Technologies, and BioAffinity Technologies. Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company was incorporated in 2007 and is headquartered in Southlake, Texas. Heart Test operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange.
Specialization
Health Care, Health Care Equipment & Services
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
CUSIP42254E112
LocationTexas; U.S.A
Business Address550 Reserve Street,
SectorHealth Care Equipment & Supplies
IndustryHealth Care
BenchmarkDow Jones Industrial
Websiteheartsciences.com
Phone682 237 7781
CurrencyUSD - US Dollar

Heart Test Key Financial Ratios

Heart Test Key Balance Sheet Accounts

202020212022202320242025 (projected)
Total Assets1.9M2.1M3.3M9.5M10.9M11.5M
Other Current Liab422.4K1.1M672.0K701.3K806.5K627.4K
Net Debt2.4M5.2M(94.6K)(4.8M)(4.3M)(4.1M)
Retained Earnings(49.6M)(54.4M)(60.8M)(67.4M)(60.6M)(63.7M)
Accounts Payable335.8K694.7K631.4K448.2K515.4K543.2K
Cash723.5K918.3K1.7M5.8M6.7M7.0M
Net Receivables94.8K2.3K319.4K876.7K1.0M1.1M
Inventory750.8K674.1K676.4K629.2K566.3K574.0K
Other Current Assets163.8K89.8K359.8K917.1K1.1M1.1M
Total Liab3.8M8.1M3.1M2.2M2.5M4.2M
Net Invested Capital970.1K15.5K1.2M7.8M9.0M9.4M
Total Current Assets1.6M1.9M2.7M7.4M8.5M8.9M
Capital Stock3.8K3.8K10.5K1.1K1.2K1.2K
Net Working Capital392.0K(1.5M)863.7K5.6M6.4M6.8M
Short Term Debt487.8K1.7M529.5K602.3K692.6K832.6K

Heart Test Key Income Statement Accounts

The reason investors look at the income statement is to determine what Heart Test's earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
202020212022202320242025 (projected)
Net Interest Income(132.5K)(371.6K)(243.2K)(354.1K)(318.7K)(334.6K)
Interest Expense132.5K371.6K243.2K354.1K407.2K242.9K
Total Revenue25.6K14.4K5.2K18.6K16.7K20.5K
Gross Profit14.9K6.5K2.4K12.5K11.3K8.6K
Operating Income(2.6M)(4.7M)(6.1M)(6.3M)(5.7M)(6.0M)
Ebit(2.3M)(4.5M)(6.1M)(6.3M)(5.6M)(5.9M)
Research Development1.7M3.0M2.5M2.9M3.3M2.7M
Ebitda(2.3M)(4.4M)(6.1M)(6.2M)(5.5M)(5.8M)
Cost Of Revenue10.7K7.9K2.8K6.1K5.5K5.2K
Income Before Tax(2.5M)(4.8M)(6.4M)(6.6M)(5.9M)(6.2M)
Net Income(2.6M)(4.6M)(490.9M)(6.6M)(5.9M)(6.2M)
Income Tax Expense129.0K(250.2K)484.5M(95.1K)(109.4K)(103.9K)

Heart Test Key Cash Accounts

202020212022202320242025 (projected)
Change To Inventory106.2K76.6K(2.2K)47.2K42.5K60.0K
Investments(712.0)(1.9K)(18.3K)(125.3K)(112.7K)(107.1K)
Change In Cash226.6K194.8K742.2K4.1M4.8M5.0M
Free Cash Flow(2.5M)(3.6M)(5.8M)(6.2M)(5.6M)(5.9M)
Depreciation33.6K26.6K26.9K95.1K109.4K114.9K
Other Non Cash Items(248.5K)(35.6K)(101.0M)539.2K485.3K509.6K
Capital Expenditures712.01.9K18.3K125.3K144.1K151.3K
Net Income(2.5M)(4.8M)(6.4M)(6.6M)(5.9M)(6.2M)
End Period Cash Flow723.5K918.3K1.7M5.8M6.7M7.0M

Heart Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Heart Test's current stock value. Our valuation model uses many indicators to compare Heart Test value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Heart Test competition to find correlations between indicators driving Heart Test's intrinsic value. More Info.
Heart Test Laboratories is rated # 2 in return on equity category among its peers. It is rated # 3 in return on asset category among its peers . At this time, Heart Test's Return On Equity is fairly stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Heart Test by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Heart Test Market Pulse

 Quote0.0403
 Change(%)  19.24 
 Change0.01 
 Open0.0499
 Low0.0403
 High0.0517
 Volume31039
 ExchangeNASDAQ

Steps to analyze company Financials for Investing

There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Heart Test is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Heart has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it.
In summary, you can determine if Heart Test's financials are consistent with your investment objective using the following steps:
  • Review Heart Test's balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
  • Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
  • Study the cash flow inflows and outflows to understand Heart Test's liquidity and solvency.
  • Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
  • Compare Heart Test's financials to those of its peers to see how it stacks up and identify any potential red flags.
  • Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Heart Test's stock is overvalued or undervalued.
Remember, these are just guidelines and should not be the only basis for investment decisions. It is always important to analyze the leading stock market indicators., conduct additional research and seek professional advice if needed.

Heart Test Thematic Clasifications

Heart Test Laboratories is part of Drugs investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Drug manufacturing and delivery. Companies involved in medical and pharmaceutical drug research, manufacturing, and delivery
DrugsView
This theme covers Drug manufacturing and delivery. Companies involved in medical and pharmaceutical drug research, manufacturing, and delivery. Get More Thematic Ideas
Today, most investors in Heart Test Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Heart Test's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Heart Test growth as a starting point in their analysis.

Price Earnings To Growth Ratio

0.005404

At this time, Heart Test's Price Earnings To Growth Ratio is fairly stable compared to the past year.

Heart Test March 25, 2025 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Heart Test help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Heart Test Laboratories. We use our internally-developed statistical techniques to arrive at the intrinsic value of Heart Test Laboratories based on widely used predictive technical indicators. In general, we focus on analyzing Heart Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Heart Test's daily price indicators and compare them against related drivers.

Additional Tools for Heart Stock Analysis

When running Heart Test's price analysis, check to measure Heart Test's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Heart Test is operating at the current time. Most of Heart Test's value examination focuses on studying past and present price action to predict the probability of Heart Test's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Heart Test's price. Additionally, you may evaluate how the addition of Heart Test to your portfolios can decrease your overall portfolio volatility.